Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a clinical diagnosis of rheumatoid arthritis for at least 6 months~* Must have at least 6 tender joints AND 6 swollen joints~* Has a C-reactive protein ≥ 1.0 mg/L OR Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/hr~* Baseline MRI must show evidence of synovitis in the wrist~* Must have screening laboratory tests within acceptable levels~* Women of childbearing potential and all men must agree to use a medically accepted method of contraception prior to entering the study and continue throughout study up to 6 weeks after study completion~* Must meet tuberculosis (TB) screening criteria~* Have received methotrexate therapy for ≥ 3 months; dose must be stable for at least 8 weeks~* If taking the a disease modifying anti-rheumatic drug (DMARD) in combination with methotrexate must be on a stable dose~* Must have a clinically acceptable 12 lead electrocardiogram (ECG)~* If taking oral corticosteroids must be on a stable dose equivalent to ≤10 mg of prednisone (or prednisolone) per day for ≥2 weeks~* If taking daily non-steroidal anti-inflammatory drug (NSAID) must be on a stable dose for ≥2 weeks; if taking NSAID on an as-needed basis must agree to discontinue use for at least 3 days and use only acetaminophen for breakthrough pain for 3 days before each MRI and clinic visit~* If received biological therapies, the last dose of these drugs was to be received ≥ 3 months prior to the baseline visit AND the reason for discontinuations was not for safety considerations OR lack of efficacy~Exclusion Criteria:~* Are pregnant, intend to become pregnant, or are breastfeeding~* Has inflammatory arthritis other than RA~* Has uncontrolled hypertension~* Has moderate or severe congestive heart failure~* Has a history of or current signs and/or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease~* Has a history of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis~* Is currently participating in another clinical study or have participated in a clinical study (e.g., laboratory or clinical evaluation) within 4 weeks~* Has history of any tumor with the exception of adequately treated basal cell carcinoma or carcinoma in situ of the cervix~* Has a history of any latent or active granulomatous infection including histoplasmosis, or coccidiomycosis~* Had a non-tuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months~* Has a history of an infected joint prosthesis which has not been removed or replaced~* Has a known hypersensitivity to human immunoglobulin proteins or other components of infliximab~* Has received rituximab or natalizumab~* Has known claustrophobia or other contraindication to MRI~* Does not meet washout period guidelines for previous treatments/injections/vaccinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): 3 mg/kg of Infliximab intravenous infusion
- Placebo (Type: PLACEBO_COMPARATOR): saline via intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).